SHORT MINI-FUTURE - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 18:42:24 17/05/2024 BST | ||
| 4.96 EUR | -9.16% |
|
| Current month | -48.39% | ||
| 1 month | -49.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 4.96 | -9.16% |
| 16/05/24 | 5.46 | -0.55% |
| 15/05/24 | 5.49 | -19.03% |
| 14/05/24 | 6.78 | +3.67% |
| 13/05/24 | 6.54 | -9.04% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 06:42 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM656C |
| ISIN | DE000VM656C5 |
| Date issued | 15/12/2023 |
| Strike | 495.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.9 € |
|---|---|
| Lowest since issue | 4.51 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
